MedTrace Logo

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

NCT03412396 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-03-19

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well apalutamide works in treating patients with prostate cancer before radical prostatectomy. Androgen can cause the growth of prostate cancer cells. Hormone therapy using apalutamide may fight prostate cancer by lowering the amount of androgen the body makes and may make it less likely for patients to receive radiation therapy after surgery.

Conditions

  • Prostate Adenocarcinoma
  • Stage IIB Prostate Cancer AJCC v8

Interventions

DRUG

Apalutamide

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

PROCEDURE

Radical Prostatectomy

Undergo radical prostatectomy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • John W Davis · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-22
Primary Completion
2024-10-03
Completion
2026-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03412396 on ClinicalTrials.gov